Rheumatoid Arthritis DMARD Intervention and UtilizationStudy
Status:
Completed
Trial end date:
2008-10-01
Target enrollment:
Participant gender:
Summary
To systematically collect and document use patterns, effectiveness and safety of DMARD
treatments currently used in the management of rheumatoid arthritis. The primary purpose of
this study is to estimate the incidence of serious adverse experiences and adverse
experiences of interest in patients with rheumatoid arthritis (RA) treated with ENBREL®.
Details
Lead Sponsor:
Amgen
Collaborators:
Immunex Corporation Wyeth is now a wholly owned subsidiary of Pfizer